SAB Biotherapeutics, Inc. (SABS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.93 |
| Open | 3.89 |
| Day High | 4 |
| Day Low | 3.86 |
| 52-Week High | 6.6 |
| 52-Week Low | 1.67 |
| Volume | 394,806 |
| Average Volume | 798,451 |
| Market Cap | 36.99M |
| PE | -6.67 |
| EPS | -0.58 |
| Moving Average 50 Days | 3.69 |
| Moving Average 200 Days | 3.52 |
| Change | -0.06 |
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
GlobeNewswire Inc.
Mar 10, 2026 11:31 AM GMT
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
Mar 09, 2026 9:16 PM GMT
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a full